[go: up one dir, main page]

WO1997044667A3 - Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules T antigene-specifiques et pour stimuler des cellules T - Google Patents

Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules T antigene-specifiques et pour stimuler des cellules T Download PDF

Info

Publication number
WO1997044667A3
WO1997044667A3 PCT/FR1997/000892 FR9700892W WO9744667A3 WO 1997044667 A3 WO1997044667 A3 WO 1997044667A3 FR 9700892 W FR9700892 W FR 9700892W WO 9744667 A3 WO9744667 A3 WO 9744667A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
specific
lymphocytes
mhc
cells
Prior art date
Application number
PCT/FR1997/000892
Other languages
English (en)
Other versions
WO1997044667A2 (fr
Inventor
Pierre Langlade-Demoyen
Yu-Chun Lone
Philippe Kourilsky
Jean-Pierre Abastado
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Pierre Langlade-Demoyen
Yu-Chun Lone
Philippe Kourilsky
Jean-Pierre Abastado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Pierre Langlade-Demoyen, Yu-Chun Lone, Philippe Kourilsky, Jean-Pierre Abastado filed Critical Pasteur Institut
Priority to AU30365/97A priority Critical patent/AU3036597A/en
Publication of WO1997044667A2 publication Critical patent/WO1997044667A2/fr
Publication of WO1997044667A3 publication Critical patent/WO1997044667A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes d'utilisation de complexes CMH/peptide. On décrit la purification réussie de lymphocytes T peptide-spécifiques par adsorption sur un support solide couplé à une densité élevée de molécules recombinantes du CMH, chargées d'un seul peptide. Cette méthode a permis d'isoler, purifier et quantifier des lymphocytes T spécifiques de tumeur, à partir d'échantillons d'exsudat péritonéal et de lymphocytes infiltrant des tumeurs. Ces populations de lymphocytes T purifiés peuvent être encore multipliées in vitro. Les cellules résultantes présentent une activité cytotoxique supérieure et une action anti-tumorale accrue par réinjection au porteur de la tumeur. Cette nouvelle approche est importante pour analyser le répertoire de lymphocytes T au niveau de la spécificité peptidique et pour améliorer de nouveaux traitements thérapeutiques basés sur l'immunothérapie adoptive à lymphocytes T. De plus, les complexes spécifiques CMH/peptide peuvent induire ou stimuler des lymphocytes T peptide-spécifiques. Ainsi, on décrit également des méthodes destinées à induire des lymphocytes T cytotoxiques (CTL). Ces CTL peuvent être utilisés à leur tour pour combattre la croissance des cellules tumorales in vitro ou in vivo. La molécule CMH recombinante chargée avec un seul peptide peut être utilisée avec efficacité sous forme polymère pour stimuler une réponse immune spécifique ex vivo ou in vivo après injection à l'homme ou l'animal.
PCT/FR1997/000892 1996-05-21 1997-05-21 Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t WO1997044667A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30365/97A AU3036597A (en) 1996-05-21 1997-05-21 Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65192596A 1996-05-21 1996-05-21
US08/651,925 1996-05-21

Publications (2)

Publication Number Publication Date
WO1997044667A2 WO1997044667A2 (fr) 1997-11-27
WO1997044667A3 true WO1997044667A3 (fr) 1998-03-19

Family

ID=24614802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/000892 WO1997044667A2 (fr) 1996-05-21 1997-05-21 Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t

Country Status (2)

Country Link
AU (1) AU3036597A (fr)
WO (1) WO1997044667A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
NZ511031A (en) * 1998-09-14 2003-11-28 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
FR2798128B1 (fr) * 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
EP1103265A1 (fr) * 1999-11-15 2001-05-30 Leids Universitair Medisch Centrum Cellules T spécifiques de protéines polymorphiques de cellules malignes
ES2747357T3 (es) * 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
CA2357906A1 (fr) * 2001-09-28 2003-03-28 Institut Pasteur Identification de nouveaux epitopes de cd8 de proteines ayant des proprietes therapeutiques et immunologiques pour lutter contre les infections a vih
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
EP2155782A2 (fr) 2007-03-26 2010-02-24 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP3620465B1 (fr) 2007-07-03 2025-02-19 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
SG172374A1 (en) * 2008-12-24 2011-07-28 Oncotherapy Science Inc C1orf59 peptides and vaccines including the same
WO2020127222A2 (fr) 2018-12-17 2020-06-25 Immudex Aps Panneau comprenant des multimères de borrelia cmh
EP4200023A4 (fr) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Cellules hla-f-modifiées et procédés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023067A1 (fr) * 1993-03-31 1994-10-13 Abbott Laboratories Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes
WO1995033995A1 (fr) * 1994-06-06 1995-12-14 Gti Procede et trousse pour detecter des anticorps
WO1995035500A1 (fr) * 1994-06-17 1995-12-28 Ludwig Institute For Cancer Research Procedes de production de lymphocytes t cytolytiques specifiques contre un complexe de peptide et de molecule de mhc
WO1996005287A1 (fr) * 1994-08-09 1996-02-22 Anergen, Inc. Procede permettant d'isoler des lymphocytes t du sang peripherique
WO1996026962A1 (fr) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigenes/mhc pour detecter et purifier les lymphocytes t specifiques aux antigenes
WO1996036881A2 (fr) * 1995-05-16 1996-11-21 Cancer Research Campaign Technology Limited Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023067A1 (fr) * 1993-03-31 1994-10-13 Abbott Laboratories Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes
WO1995033995A1 (fr) * 1994-06-06 1995-12-14 Gti Procede et trousse pour detecter des anticorps
WO1995035500A1 (fr) * 1994-06-17 1995-12-28 Ludwig Institute For Cancer Research Procedes de production de lymphocytes t cytolytiques specifiques contre un complexe de peptide et de molecule de mhc
WO1996005287A1 (fr) * 1994-08-09 1996-02-22 Anergen, Inc. Procede permettant d'isoler des lymphocytes t du sang peripherique
WO1996026962A1 (fr) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigenes/mhc pour detecter et purifier les lymphocytes t specifiques aux antigenes
WO1996036881A2 (fr) * 1995-05-16 1996-11-21 Cancer Research Campaign Technology Limited Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. GODEAU ET AL.: "Purification and ligand binding of a soluble class I major histocompatibility complex molecule consisting of the first three domains of H-2Kd fused to beta2-microglobulin expressed in the baculovirus-insect cell system.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 5, 1992, pages 24223 - 24229, XP002051156 *
TOSHITANI, KOJI ET AL: "Expression of a single chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes", PROC. NATL. ACAD. SCI. U. S. A. (1996), 93(1), 236-40 CODEN: PNASA6;ISSN: 0027-8424, XP002051157 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
WO1997044667A2 (fr) 1997-11-27
AU3036597A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
WO1997044667A3 (fr) Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules T antigene-specifiques et pour stimuler des cellules T
Tang et al. T cell exhaustion and CAR‐T immunotherapy in hematological malignancies
Miller et al. Role of monocytes in the expansion of human activated natural killer cells
JP2540544B2 (ja) リンフオカイン活性化されたキラ−細胞の製法
CN103232973B (zh) 一种k562细胞扩增激活nk细胞的方法
CA2205430C (fr) Procede de fabrication d'un medicament destine au traitement de l'immunodeficience secondaire
AU3912497A (en) Purification of antigen-specific t cells
Zhang et al. Treg: a promising immunotherapeutic target in oral diseases
Xv et al. Mesenchymal stem cells moderate immune response of type 1 diabetes
US20070172947A1 (en) Methods and compositions for expanding T regulatory cells
JP2002510655A (ja) 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
KR20160093090A (ko) 관절염 증상 치료용 조성물
Xu et al. A limited course of soluble CD83 delays acute cellular rejection of MHC‐mismatched mouse skin allografts
Chen et al. Effects of IL‐10‐and FasL‐overexpressing dendritic cells on liver transplantation tolerance in a heterotopic liver transplantation rat model
CN102027104A (zh) 含有细胞因子诱导杀伤细胞的细胞群的制造方法
Oberholtzer et al. Adoptive transfer of regulatory immune cells in organ transplantation
WO2017069512A1 (fr) Procédé d'induction et de prolifération de cellules t spécifiques d'un antigène viral
Wan et al. The potential of regulatory T cell-based therapies for alopecia areata
Morgan et al. Induction of IL-1 secretion from human monocytes by Fc region subfragments of human IgG1.
Morgan et al. Human C3a-mediated suppression of the immune response. I. Suppression of murine in vitro antibody responses occurs through the generation of nonspecific Lyt-2+ suppressor T cell.
Elkins et al. Constitutive production of a factor supporting B lymphocyte differentiation by a T cell hybridoma.
Lindemann et al. Lymphokine activated killer cells
Yu et al. Prolonged survival time of allografts by the oral administration of RDP58 linked to the cholera toxin B subunit
CN112941030B (zh) 一种抗原特异性Treg及其制备方法和应用
Dabrowski et al. The role of dendritic cells as co-stimulators in tolerance induction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97541722

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase